Brainomix’s e-Lung better identifies high risk lung fibrosis patients

Published: 27-Mar-2024

WRVS was able to predict both short and long-term patient outcomes, including lung function decline and survival

Brainomix, the AI-powered medtech company, announces the publication of a new study, finding that its e-Lung — an AI-enabled CT processing software — successfully stratifies patients at risk of IPF progression.

The novel technology was also found to outperform standard measures, which demonstrates its potential role in improving efficiency of future clinical trials.

The trial features in the peer-reviewed American Journal of Respiratory and Critical Care Medicine1, resulting from a research collaboration AstraZeneca, the UK’s leading Biopharmaceutical company.

The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). 

The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.

Dr Peter George, Senior Medical Director at Brainomix, and Clinical Lead for ILD at Royal Brompton Hospital in London, said: “In this analysis of AstraZeneca’s IPF clinical trial, we have shown that from a single baseline CT scan, WRVS is able to identify patients at risk of decline in Forced Vital Capacity (FVC) over the next 52 weeks, outperforming standard measures.”

“These data suggest that the e-Lung WRVS tool may allow for enrichment of clinical trials with progressive patients, could identify patients at low risk of IPF progression, might facilitate well-matched treatment arms and could reduce the size of future clinical trials.

This study comes on the back of previously published data that was presented last year at the American Thoracic Society (ATS) meeting in Washington, D.C., which showed that WRVS was more strongly associated with transplant free survival of IPF patients than FVC alone. 

WRVS was also able to predict both short- and long-term outcomes of the patients, including lung function decline and survival. 

The collaboration with AstraZeneca was driven by Brainomix’s Life Sciences division. 


You may also like